bioRxivCancer BiologyPreprint
Functional Characterization of Myeloid Neoplasm-associated DDX41 Variants Reveals Pathogenic Interaction with Acquired Hotspot Mutation
Julianna Fisher, Emily StepanchickiD, Andrew Wilson, 木田 潤一郎, Mike AdamiD, Mariela V. Perez Otero, Talha BadariD, Yael N. KusneiD, Alejandro FerreriD, Mrinal M. PatnaikiD, Timothy M. ChloniD
Abstract
Germline variants in DDX41 are the most frequent genetic predisposition to adult hematologic malignancies. The most common variants are truncating, implicating loss of function in the pathogenesis. However, non-truncating variants account for 30-40% of cases, and their impact on essential DDX41 functions remains unknown. We utilized a genetic complementation assay to assess the functionality of 10 recurrent germline non-truncating variants of DDX41. All variants restored viability to Ddx41-deficient hematopoietic progenitor cells at exogenous expression levels. In contrast, the hotspot mutant p.R525H, which is somatically acquired at disease onset in >50% of patients, failed to restore viability. CRISPR-based modeling in cell lines and mice revealed heterogeneity: some variants were non-functional at endogenous expression levels whereas others maintained complete functionality, supporting normal cell proliferation and even lifelong hematopoiesis in a homozygous setting. Notably, co-expression of p.R525H with some variants caused impaired hematopoietic progenitor cell viability, indicating a dominant-negative effect of p.R525H. In contrast, other variants, all classified as variants of unknown significance, were unaffected by the presence of p.R525H. A screen of 100 disease-associated variants confirmed that many non-truncating germline variants are susceptible to p.R525H-mediated dominant-negative effects, whereas wild-type DDX41 is not. These findings indicate that DDX41 variant curation is complicated by variable effects on functionality and variant-specific interactions with somatically-acquired DDX41 mutations. The dominant-negative effect of p.R525H provides a mechanistic basis for the conclusion of recent patient cohort analyses that co-occurrence with a somatic hotspot mutation is a reliable indicator of DDX41-driven disease in carriers of non-truncating variants.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Somatic DDX41 mutations confer neomorphic splicing activity in the pathogenesis of myelodysplastic neoplasms
Rasika Venkataraman, Noemi Puccio, … Stanley Chun-Wei Lee·bioRxiv·Sep 24, 2026
- Genomic Landscape of Patients with Germline RUNX1 Variants and Familial Platelet Disorder with Myeloid Malignancies in a Natural History Study
Kai Yu, Natalie T Deuitch, … Paul Liu·Blood AdvancesPeer-reviewed·Nov 29, 2023
- DDX41 is needed for pre-and post-natal hematopoietic stem cell differentiation in mice
Jing Ma, Nadim Mahmud, … Susan R. Ross·bioRxiv·Aug 13, 2021
- DDX41 dissolves G-quadruplexes to maintain erythroid genome integrity and prevent cGAS-mediated cell death
Honghao Bi, Kehan Ren, … Peng Ji·Nature CommunicationsPeer-reviewed·Aug 5, 2025
- Pathogenicity evaluation of coding germline variants identifies rare alleles enriched in hematological patients of a founder population
Jessica Koski, Laura Langohr, … Outi Kilpivaara·medRxiv·Oct 23, 2024
- RUNX1 haploinsufficiency causes a marked deficiency of megakaryocyte-biased hematopoietic progenitor cells: Mechanistic studies and drug correction
Brian Estevez, Sara Borst, … Mortimer Poncz·bioRxiv·Aug 23, 2020